GAP President to FDA: Full Approval of Leqembi

Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation:

(WASHINGTON, DC, JUNE 12) – “Last week, I was proud to participate in the open public hearing session at the Food and Drug Administration (FDA)’s Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting in support of full approval of Leqembi.

I wholeheartedly applaud the committee for voting unanimously to approve Leqembi for the treatment of Alzheimer’s disease.

For people living with Alzheimer’s, everyday counts. This treatment has been shown to significantly lower amyloid plaque buildup in the brain, and that will mean that people on this therapy have a better chance of maintaining a good quality of life.”


About the Global Alzheimer’s Platform (GAP) Foundation

The Global Alzheimer’s Platform Foundation (GAP) is a patient-centric, non-profit organization dedicated to speeding the delivery of innovative therapies to those living with Alzheimer’s by reducing the time and cost of Alzheimer’s disease clinical trials, and by increasing diversity in clinical research.

To top